CKD Bio KRX:063160KOSPI
종근당바이오 · Korean news coverage and regulatory filings, organized.
Articles, 24h1
Articles, 7 days1
DART filings, 7 days1
Articles tracked5since Sep 11
In Q2 2026, CKD Bio reported revenue of ₩41.1bn, down 0.3% year on year, and an operating loss of ₩5.0bn. CKD Bio (종근당바이오) appeared in 1 Korean news article and 1 DART filing over the past seven days. Coverage peaked on Oct 19 with 1 article.
Filing signals Swung to loss Dividend cut Screener
CKD Bio quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩41.1bn | -0.3% | −₩5.0bn margin −12.2% | −₩5.4bn |
| Q1 2026 | ₩40.7bn | -4.3% | −₩1.7bn margin −4.2% | −₩2.0bn |
| Q4 2025 derived | ₩42.2bn | +34.4% | ₩109m margin 0.3% | −₩1.1bn |
| Q3 2025 | ₩34.1bn | -22.3% | −₩1.5bn margin −4.3% | −₩2.2bn |
| Q2 2025 | ₩41.2bn | -19.1% | ₩2.9bn margin 7.0% | −₩480m |
| Q1 2025 | ₩42.5bn | -6.6% | ₩2.1bn margin 4.9% | ₩900m |
| Q4 2024 derived | ₩31.4bn | -11.1% | ₩209m margin 0.7% | ₩1.2bn |
| Q3 2024 | ₩43.9bn | +3.6% | ₩2.6bn margin 5.9% | ₩285m |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
CKD Bio top stories 2 weeks, by number of outlets
- 1
- 2